Randall Lutter, the FDA's acting deputy commissioner for policy, was quoted: "We are very interested in ensuring we have the best possible access to scientific experts. At the same time, we seek to ensure we have the fullest public confidence in the integrity of our advisory committee process."
Curiously, although Lutter's comment is directed to the problem of an expert favorably reviewing the expert's own products, the comment could equally well be applied to peer to patent, wherein an expert at company A might UNFAVORABLY review the patents of his competitor, company B.
IPBiz mentioned the FDA issue before: Conflicts of interest at the FDA
Lutter and Warner said the $50,000 figure would not apply to research grants made by pharmaceutical companies to universities where the scientists work, only to grants given directly to experts.
There's something here for CIRM to think about.